Thermo Fisher Pricing Spineometer: 5 of 5 Vertebrae

Thermo Fisher, a global life sciences company specializing in instruments, consumables, and services, had a positive 2024. Revenue rose 0.1% to $42.9 billion and earnings before interest and taxes rose 7% to 7.3 billion over last year.

A review of Thermo Fisher’s 24 April 2025 earnings call and the 2024 annual financial report provided insight regarding the importance of pricing on performance.

FACTS FROM EARNINGS CALL AND ANNUAL REPORT

Thermo Fisher has four operating segments.

Life Science Solutions provides reagents, instruments, and consumables. It serves biosciences customers for biological and medical research, genetic customers for genomic and proteomic solutions, and bioproduction customers for biological-based therapeutics and vaccines.

Analytical Instruments provides instruments and consumables for chromatography, mass spectrometry, chemical analysis, and electron microscopy. These instruments are used for scientific research, applied technology, production, analysis, and field instrumentation in life science, material science, and semiconductor fields.

Specialty Diagnostics provides diagnostic kits, reagents, culture media, and instruments to healthcare, pharmaceutical, industrial, and food safety laboratories.

Laboratory Products and Biopharma Services provides outsourced services to the pharmaceutical and biotech customers for drug development, clinical research, and manufacturing.

Marc Casper, CEO, spoke to the challenge of managing tariffs in today’s economic environment. “I think it’s important to note that with thinking appropriate pricing actions, we’re not trying to take advantage of a situation, and this is exactly what we’ve done in prior times and appropriately passing price on.”

In the current environment, Marc Casper is focused on delivering profit dollars, not margin percentage, stating, “We’re taking the right actions and protecting the profit dollars, but it has an impact on our reported margin.”

VALUE-BASED PRICING FRAMEWORK IMPLIED PRICING REQUIREMENTS

Of the 125,000 professionals at Thermo Fisher stationed globally, broad industry benchmarks would suggest 85 to 430 dedicated to pricing. Narrow industry benchmarks considering the industry, global footprint, and customer complexity would suggest Thermo Fisher to be placed at the upper end of this range.

1. Thermo Fisher has multiple sales channels, including direct sales, customer services, e-commerce, and third-party distribution, and roughly 15,000 customer-facing sales professionals. Price variance management, also known as commercial policy, must incorporate channel strategy and cost-to-serve for managing horizontal channel conflict. Without this consideration, one channel can undercut another channel in price, thus shifting sales between channels while also reducing price capture from channels and the end customers. Also, direct sales and customer service presumably provide value-added information to customers at a higher cost to serve than e-commerce channels. A strategy might be to monitor and develop the entire customer relationship across channels, yet this, too, has sales incentive alignment challenges.
2. Thermo Fisher is exposed to multiple macroeconomic threats. As a global company, country-specific productivity growth or recessions, currency fluctuations, challenges in logistics, geopolitical risk, and much more would impact demand and pricing power. Applied economists would enable executives at Thermo Fisher to distinguish between competitive dynamics, price change challenges, and demand change challenges for delivering more accurate price responses to changes in volume demand. The appropriate price response to a shift in industry demand or supply curves is significantly different from that of a competitive price change.
3. Thermo Fisher has a complex array of products, both consumables and durables. This requires shifting from price management techniques between competition-based pricing and value—based pricing depending on the offering.
4. High-value offerings, such as mass spectrometry, chromatography, and electron microscopy, would benefit from pricing based on the differential value delivered to customers. This requires a combination of Economic Value to Customer calculations and, for some high-revenue offerings, conjoint analysis to get the starting price right.
5. Selling consumables and durables to customers may benefit from a legal form of tying arrangement and calculations of customer lifetime value if the sale and use of consumables is protected via warranties on durables which become invalid if an alternative, competing consumable is used. Executing this strategy requires working with legal and product design, if undertaken.
6. Thermo Fisher invests heavily in innovation and new product development, with 3.2% of revenue dedicated to Research & Development. New product development (NPD) efforts would benefit from pricing’s engagement early in the development cycle to estimate the value of the NPD effort and again late in the cycle to define the go-to-market price prior to sales engagement. This often requires pricing to have a clearly defined engagement role throughout the NPD cycle.
7. Thermo Fisher is a global company with significant operations in the Americas, Europe, the Middle East, Africa, and Asia Pacific. Pricing would need to have a global footprint as well to match the commercial policy and competitive changes required for different geographies.
8. New competitors are emerging in this market. Thermo Fisher would also need to consider its competitive price reaction matrix to determine when a price response is needed versus when other marketing levers should be pulled to address an emerging competitive threat.
9. Price discipline would need to be enforced, requiring both artificial intelligence applied to proprietary transactional data and strong relationships with commercial teams globally.
10. Thermo Fisher serves a wide variety of customers from pharmaceutical and biotech, hospitals and clinical diagnostics, universities, research institutes, to government agencies. This requires a strong commercial policy and, when engaging government agencies, strong price discipline.

OBSERVED PRICING CAPABILITY

Research into the investment by Thermo Fisher Scientific in pricing yielded encouraging results.

1. The pricing team was well within the broad industry benchmark range and may well be in the narrower company expectation range at the upper end of the expectations.
2. Pricing roles ranged from leader, analyst, and manager, to director and vice president.
3. Pricing responsibilities spanned global, regional, industry, channel, operations, strategy, and other areas.

Given the importance and capability of pricing at Thermo Fisher Scientific, as indicated in financial reports, management statements, and our pricing team research, and given their performance, we have come to the following conclusion as of June 2025.

Thermo Fisher Scientific Pricing Spineometer: 5 out of 5 Vertebrae. Though opportunities for improvement are likely to be found, Thermo Fisher management and actions indicate a strong pricing capability.

TMO (Thermo Fisher Scientific Inc.) fell from 426 the day prior to their earnings call to 419 one week later. FY 2024 revenue of $42.9 billion with a 17% operating margin and P/E ratio near 20.

For FY 2024, a 1% improvement in price would yield a 6% improvement in operating profits, holding all else constant, at Thermo Fisher Scientific